



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Gastroenteritis, Hepatitis, Encephalopathy, and Human Herpesvirus 6 Detection in an Immunocompetent Child: Benefits and Risks of Syndromic Multiplex Molecular Panel Testing

Christina A. Olson, MD^{1,2}, Samuel R. Dominguez, MD, PhD^{1,2}, Steve Miller, MD, PhD³, Charles Y. Chiu, MD, PhD^{3,4,5}, and Kevin Messacar, MD^{1,2}

An immunocompetent toddler came to medication attention with gastroenteritis, complicated by encephalopathy and hepatitis. Multiplexed testing using a polymerase chain reaction meningitis panel was positive for human herpesvirus 6 (HHV-6). Clinical correlation, quantitative HHV-6 polymerase chain reaction, and metagenomic next-generation sequencing supported a likely diagnosis of primary HHV-6B infection. (*J Pediatr* 2019;212:228-31).

Human herpesvirus 6 (HHV-6) infects 90% of children by 2 years of age¹ and accounts for 10% of visits to the emergency department for febrile illness in the first 3 years.² The classic presentation is a self-limited high fever followed by a rash, the illness known as roseola infantum or sixth disease.³ The rapid temperature rise also can be associated with seizures, accounting for one-third of febrile seizures before 2 years of age.² In immunocompromised patients, HHV-6 is a well-recognized cause of severe disease.⁴⁻⁶ In clinical practice, however, the frequency and potential for severe HHV-6 infection in immunocompetent children is likely under-recognized because of a lack of routine clinical testing.

HHV-6 has been included in a multiplex polymerase chain reaction (PCR) meningitis/encephalitis panel for pathogen detection from cerebrospinal fluid (CSF) (BioFire FilmArray Meningitis/Encephalitis (ME) panel; BioMérieux).⁷ Multiplexed testing has the potential to identify a broader clinical spectrum of acute infection in immunocompetent children, as testing for HHV-6 alone is rarely pursued. Results must be interpreted cautiously, however, because qualitative DNA detection alone is insufficient evidence for active infection.⁸ Clinical judgment and consideration of secondary quantitative DNA testing (in the CSF, serum and/or whole blood) is required when HHV-6 is detected in CSF on a syndromic multiplex PCR panel. We describe a previously healthy child with severe gastroenteritis, hepatitis, and encephalopathy because of probable primary HHV-6B infection, a constellation of symptoms predominantly described in immunocompromised patients.

Case

A 13-month-old male child came to medical attention with vomiting, diarrhea, and dehydration. His past medical his-

tory was unremarkable. There were no prior hospitalizations, unusual infections, or concerns about growth. A sibling was ill with similar but milder symptoms, and there was no concerning travel, food, or animal exposure history.

Following hospitalization with a diagnosis of viral gastroenteritis and failure of oral fluid challenge, he developed fever and prolonged somnolence but no meningeal signs, seizures, or focal neurologic deficits. He also failed several trials off intravenous fluids, with associated deterioration in perfusion and alteration in mental status.

A blood gas, comprehensive serum metabolic panel, complete blood count, and abdominal radiographs were performed on hospital day 2, and all results were unremarkable. Because of ongoing symptoms, the laboratory tests were repeated on hospital day 5; in the interim, his white blood count had doubled, platelet count had dropped, and serum hepatic transaminases, lactate dehydrogenase, and ferritin had increased markedly. Testing for erythrocyte sedimentation rate, C-reactive protein, liver function, acetaminophen level, lactate and triglyceride levels, inborn errors of metabolism, cortisol, and antinuclear antibodies were normal, as was an echocardiogram and brain magnetic resonance imaging. Peripheral blood smears showed no evidence of malignancy or hemophagocytosis (Table).

A stool PCR panel (BioFire FilmArray gastrointestinal panel; BioMérieux) was positive for *Clostridium difficile*, but testing of nasal washings for respiratory pathogens (BioFire FilmArray respiratory pathogen panel), serum for

CSF	Cerebrospinal fluid
HHV-6	Human herpesvirus 6
mNGS	Metagenomic next-generation sequencing
PCR	Polymerase chain reaction

From the ¹Department of Pediatrics, University of Colorado School of Medicine; ²Children's Hospital Colorado, Aurora, CO; ³Department of Laboratory Medicine, University of California San Francisco; ⁴University of California San Francisco—Abbott Laboratories Viral Diagnostics and Discovery Center; and ⁵Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, CA

Supported by National Institutes of Health (1K23AI128069-01), the Charles and Helen Schwab Foundation, the George and Judy Marcus Foundation, and the California Initiative to Advance Precision Medicine. These funding sources had no role in study design or writing of the manuscript and the views expressed are solely those of the authors. The authors declare no conflicts of interest.

0022-3476/\$ - see front matter. © 2019 Elsevier Inc. All rights reserved.
<https://doi.org/10.1016/j.jpeds.2019.04.058>

Table 1. Selected laboratory testing

Laboratory studies	Hospital day 2 result	Hospital day 5 result	Reference values/units
White blood cell count	6.9	14.2	7.7-13.7 × 10 ³ /uL
Neutrophils	46	38	%
Bands	22	0.4	%
Lymphocytes	21	56	%
Hemoglobin	11.2	11.2	10.3-13.8 g/dL
Platelet count	278	97	150-500 × 10 ³ /uL
Erythrocyte sedimentation rate		1	0-15 mm/h
C-reactive protein		<0.5	0-0.9 mg/dL
Ferritin		1920	10-60 ng/mL
Lactate dehydrogenase		3896	500-920 U/L
Total bilirubin	0.2	0.2	0.2-1.2 mg/dL
Alkaline phosphatase	131	163	129-291 U/L
Aspartate aminotransferase	32	1053	20-60 U/L
Alanine aminotransferase	21	482	5-45 U/L
Stool PCR panel			
<i>Clostridium difficile</i> detected*			
Respiratory PCR panel			
No target detected†			
CSF PCR panel			
HHV-6 detected‡			
HHV-6 quantitative PCR tests			
CSF: 21 630 copies/mL (no reference range)			
Serum: 146 340 copies/mL (no reference range)			

**Cryptosporidium*, *Cyclospora cayetanensis*, *Entamoeba histolytica*, *Giardia lamblia*, adenovirus, astrovirus, norovirus, rotavirus, sapovirus, *Campylobacter* spp, *Escherichia coli* spp, *Shigella* spp, *Salmonella* spp, *Yersinia enterocolitica*, *Vibrio* spp not detected.

†Adenovirus, coronavirus, human metapneumovirus, rhinovirus, enterovirus, influenza, parainfluenza, respiratory syncytial virus, pertussis, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* not detected.

‡*Escherichia coli*, *Haemophilus influenzae*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Cryptococcus* spp, cytomegalovirus, enterovirus, herpes simplex virus, parechovirus not detected.

infection because of Epstein-Barr virus viral capsid antigen IgG/IgM, hepatitis A virus IgM, hepatitis E virus IgM, and parvovirus IgM, as well as blood, urine, and CSF bacterial cultures were negative.

A CSF PCR panel (BioFire FilmArray ME panel, BioMérieux) obtained on hospital day 6, performed on a CSF specimen with 3 white blood cells/ μ L, 0 red blood cells/ μ L, and normal protein and glucose, was positive for HHV-6. All other panel targets, including enterovirus, parechovirus, and herpes simplex virus, were negative. Follow-up quantitative HHV-6 PCR testing on the CSF and serum were remarkable for HHV-6 viral loads of 21 630 copies/mL and 146 340 copies/mL, respectively (Table). Clinical metagenomic next-generation sequencing (mNGS) of CSF was performed, which detected 4517 sequence reads spanning 67% of the genome of HHV-6, confirmed as subtype B (HHV-6B) by phylogenetic analysis (Figure); no other bacterial, viral, parasitic, or fungal pathogen was detected by mNGS. The patient developed a viral exanthem on hospital day 7 with defervescence, further supporting a diagnosis of primary HHV-6 infection. His state of alertness and well-being, examination, and laboratory abnormalities improved with supportive care, and he was discharged on hospital day 13.

Discussion

HHV-6 generally is considered a benign infection in immunocompetent children, but this case suggests that HHV-6 should be considered in otherwise healthy patients with clinical manifestations of more severe illness, such as gastro-

enteritis, hepatitis, and/or encephalopathy. Though not commonly associated with these clinical conditions, studies show that children with HHV-6 are more likely to have diarrhea than age-matched controls (26% vs 11% $P = .05$),¹ and hepatitis has been associated with HHV-6 in infants^{10,11} and stem-cell and solid organ transplant patients.^{12,13}

This case also demonstrates that liver and central nervous system involvement may not be present initially, warranting repeated laboratory testing if symptoms persist beyond a few days. Although this patient lacked features for an encephalitis diagnosis according to International Encephalitis Consortium criteria (seizures, focal neurologic abnormalities, pleocytosis, neuroimaging changes),¹⁴ the presence of HHV-6 DNA in the CSF was associated with encephalopathy without an alternative explanation (broad-based CSF multiplex PCR and mNGS testing were negative for other pathogens). Normal CSF white blood cell counts are well-described in HHV-6 central nervous system infection, which supports a role for HHV-6 testing in the setting of encephalopathy regardless of pleocytosis.⁶

Qualitative detection of HHV-6 DNA alone does not establish the virus as the cause of an illness. Chromosomal integration of HHV-6 is present in 1% of the population,¹⁵ often passed through the germline in newborns. With chromosomal integration, HHV-6 DNA is detectable in all nucleated cells, often present in CSF, persistent over time,¹⁶ and present in blood at high viral loads. HHV-6 also can establish latency in monocytes and macrophages following primary infection. Although detection of reactivated herpesviruses can represent serious illness in immunocompromised




Figure. mNGS and phylogenetic analysis of HHV-6 from patient's CSF. **A**, Coverage map. A total of 4517 HHV-6 reads obtained by CSF mNGS were mapped to the most closely matched viral genome in the National Center for Biotechnology Information GenBank database using the SURPI+ pipeline (Naccache et al⁹). There is approximately 68% coverage of the HHV-6 genome. **B**, Phylogenetic tree. The patient's assembled consensus genome was aligned in parallel with 12 representative HHV-6 genomes and the genome of murine roseolovirus (as an outgroup) from National Center for Biotechnology Information GenBank using MAFFT software (Kazutaka Katoh, Computational Biology Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan) at default settings, followed by tree construction using PHYML software (Stephane Guindon, Montpellier Bioinformatics, Montpellier, France). By phylogenetic analysis, the genotype corresponding to the patient's strain is HHV-6B.

patients,¹⁷ their detection usually is unrelated to the primary cause of disease in immunocompetent hosts.

Additional laboratory studies are available to distinguish chromosomally integrated HHV-6 DNA from active or reactivated infection. For example, a whole blood quantitative PCR result greater than 5.5 log copies/mL of blood¹⁸ or serial tests showing persistently high levels of HHV-6 DNA over time support a diagnosis of chromosomal integration. Acute and convalescent serologic testing is another method to distinguish active infection from reactivation or chromosomally integrated DNA. However, serial testing may be unavailable or impractical for use in the clinical setting, particularly when a timely diagnosis is needed. This patient's young age made reactivation unlikely, and his eventual development of a characteristic roseola-type exanthem with self-resolution of fever was highly consistent with primary

HHV-6 infection. As a result, definitive laboratory confirmation was not performed.

Besides describing a unique constellation of symptoms in an immunocompetent patient with likely primary HHV-6 infection, this case demonstrates both the advantages and challenges associated with the clinical use of multiplexed testing such as syndromic multiplex PCR panels or mNGS. Detection of nucleic acid from a pathogen consistent with the clinical presentation, such as HHV-6 in this case, can support a diagnosis that informs management and limits unnecessary testing or treatment. However, nonpathogenic organism detection may lead to incorrect assumptions of cause-and-effect, increase utilization of ineffectual and potentially harmful therapies, and impede evaluation and management of the true diagnosis. This patient's positive *Clostridium difficile* PCR result most likely represented

colonization based on his age,¹⁹ and lack of diarrhea with blood or mucous in stools or recent antibiotic use. Multiplex test results should be interpreted in the clinical context with consideration of the pre-test probability for each potential pathogen detected. ■

We thank the Children's Hospital Colorado microbiology laboratory staff who coordinated the additional laboratory testing.

Submitted for publication Jan 12, 2019; last revision received Apr 23, 2019; accepted Apr 28, 2019.

Reprint requests: Christina A. Olson, MD, Children's Hospital Colorado, 13123 E 16th Ave, B270, Aurora, CO 80045. E-mail: Christina.olson@childrenscolorado.org

References

- Zerr DM, Meier AS, Selke SS, Frankel LM, Huang M, Wald A, et al. A population-based study of primary human herpesvirus 6 infection. *N Engl J Med* 2005;352:768-76.
- Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. *N Engl J Med* 1994;331:432-8.
- Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. *Lancet* 1988;1:1065-7.
- Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. *Bone Marrow Transplant* 2015;50:1030-6.
- Fotheringham J, Akhyani N, Vortmeyer A, Donati D, Williams E, Oh U, et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. *J Infect Dis* 2007;195:450-4.
- Seeley WW, Marty FM, Holmes TM, Upchurch K, Soiffer RJ, Antin JH, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. *Neurology* 2007;69:156-65.
- Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S, et al. Multicenter evaluation of the BioFire FilmArray meningitis encephalitis panel for the detection of bacteria, viruses and yeast in cerebrospinal fluid specimens. *J Clin Microbiol* 2016;54:2251-61.
- Green DA, Pereira M, Miko B, Radmard S, Whittier S, Thakur K. Clinical significance of human herpesvirus 6 positivity on the FilmArray meningitis/encephalitis panel. *Clin Infect Dis* 2018;67:1125-8.
- Naccache SN, Federman S, Veeraghavan N, Zaharia M, Lee D, Samayoa E, et al. A cloud-compatible bioinformatics pipeline for ultra-rapid pathogen identification from next-generation sequencing of clinical samples. *Genome Res* 2014;24:1180-92.
- Mendel I, de Matteis M, Bertin C, Delaporte B, Maguer D, Collandre H, et al. Fulminant hepatitis in neonates with human herpesvirus 6 infection. *Pediatr Infect Dis J* 1995;14:993-7.
- Asano Y, Nakashima T, Yoshikawa T, Suga S, Yazaki T. Severity of human herpesvirus-6 viremia and clinical findings in infants with exanthem subitum. *J Pediatr* 1991;118:891-5.
- Hill JA, Myerson D, Sedlak RH, Jerome KR, Zerr DM. Hepatitis due to human herpesvirus 6B after hematopoietic cell transplantation and a review of the literature. *Transpl Infect Dis* 2014;16:477-83.
- Yoshikawa T. Human herpesvirus 6 causes hepatitis in transplant recipients. *Intern Med* 2006;45:417-8.
- Venkatesan A, Tunkel AR, Bloch KC, Luring AS, Sejvar J, Bitnun A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. *Clin Infect Dis* 2013;57:1114-28.
- Kauffer BB, Flamand L. Chromosomally integrated HHV-6: impact on virus, cell and organismal biology. *Curr Opin Virol* 2014;9:111-8.
- Ward KN, Leong HN, Thiruchelvam AD, Atkinson CE, Clark DA. Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. *J Clin Microbiol* 2007;45:1298-304.
- Ogata M, Satou T, Kadota J, Saito N, Yoshida T, Okumura H, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. *Clin Infect Dis* 2013;57:671-81.
- Pellet PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, et al. Chromosomally integrated human herpesvirus 6: questions and answers. *Rev Med Virol* 2012;22:144-55.
- Shim JO. *Clostridium difficile* in children: to treat or not to treat? *Pediatr Gastroenterol Hepatol Nutr* 2014;17:80-4.